Kathy Lueders will lead the future of human space flight at NASA. Photo via nasa.gov

NASA has named its new head of human space flight — a department based out of Houston's Johnson Space Center.

Kathy Lueders, formerly the commercial crew program manager, has been named associate administrator of the Human Exploration and Operations (HEO) Mission Directorate by NASA Administrator Jim Bridenstine on Friday, June 12.

"Kathy gives us the extraordinary experience and passion we need to continue to move forward with Artemis and our goal of landing the first woman and the next man on the Moon by 2024," says Bridenstine in a news release. "She has a deep interest in developing commercial markets in space, dating back to her initial work on the space shuttle program."

Lueders has been with NASA for over 12 years — spending time at both JSC and Kennedy Space Center in Florida.

"From Commercial Cargo and now Commercial Crew, she has safely and successfully helped push to expand our nation's industrial base," continues Bridenstine. "Kathy's the right person to extend the space economy to the lunar vicinity and achieve the ambitious goals we've been given."

The appointment was effective immediately, and included two other personnel changes for NASA — Steve Stich was named commercial crew program manager, and Ken Bowersox returns to his role as HEO deputy associate administrator.

"I want to thank Ken and the entire HEO team for their steady support of Kathy in making Commercial Crew such a success," added Bridenstine. "I know they'll give her the same support as she moves out in her new role. This is such a critical time for the agency and for HEO."

The appointment comes at a time when NASA is focused on commercializing space exploration. Last month, Robert Behnken and Douglas Hurley took off toward the International Space Station in SpaceX's Falcon 9 rocket — representing the first manned mission in a SpaceX vehicle and the first launch from United States soil in almost a decade.

"We still need to bring Doug and Bob home safely and we're not going to lose focus," continues Bridenstine. "We have our sights set on the Moon and even deeper into space, and Kathy is going to help lead us there."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”